In this study, we unveiled an unprecedented interplay between MSCs, neurons and myeloid cells through which MSCs inhibit aberrant NV and promote revascularization in retinopathy, at least in part, by restoring neuronal Sema3E levels and reducing pathological levels of IL-17A in myeloid cells. This evidence concerns the gene IL17A and retinal disorder.